Inhibikase Therapeutics price to book ratio IKT

Market value divided by the book value of the company's net assets, since 2021.

Today, Oct 23, 2026: 1.4×
5-year median: 1.1×
Against its 5-year history: 65th; percentile: 0 is its lowest day, 100 its highest
5-year range: 0.2× to 7.5×
Peer median: 4.1×

Inhibikase Therapeutics' price to book ratio is 1.4× as of Oct 23, 2026.

That is above its 5-year median of 1.1×, higher than on 65% of days in the last 5 years.

Over that time it ranged from 0.2× in Oct 2023 to 7.5× in Jun 2021.

The median for 3 biotech stocks of a similar size is 4.1×.

Price to book ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	1.4×	1.3×	2.3×
2025	2.1×	1.2×	2.1×
2024	4.2×	0.6×	4.2×
2023	0.5×	0.2×	0.9×
2022	0.5×	0.4×	1.0×
2021	0.9×	0.9×	7.5×

Against its peers

Companies in Biotechnology nearest Inhibikase Therapeutics' size, closest first, today.

Company	Price to book ratio
IKTInhibikase Therapeutics	1.4×
PLXProtalix BioTherapeutics	2.9×
MGTXMeiraGTx	4.1×
VCELVericel	5.9×
Peer median	4.1×

What the price to book ratio tells you

Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.

Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.

More on Inhibikase Therapeutics

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.